The impact of nail disorders on quality of life

Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life

“…It has been shown that no statistically significant difference can be found on the impact of QoL between patients with nail disorders involving only fingernails or only toenails . Thus, fingernails and toenails were hypothesized to have similar impacts on the QoL of patients with paronychia.…”

“…It has been shown that no statistically significant difference can be found on the impact of QoL between patients with nail disorders involving only fingernails or only toenails. 22 Thus, fingernails and toenails were hypothesized to have similar impacts on the QoL of patients with paronychia. The current study provides further information that severe paronychia of the bilateral thumbs or bilateral big toes does not have a greater impact on DLQI scores.…”

Onychomycosis: A study of self-recognition by patients and quality of life

“…[16] Another study revealed that patients with toenail onychomycosis had low self-esteem and were less pleased to participate in social activities. [26] In this study, higher DLQI score on symptoms and daily activities was significantly associated with the female sex.…”

“…[13][14][15] Fungal nail infection can significantly affect the physical, psychological, and social aspects of life of a patient. [1,[16][17][18][19]20] The Dermatology Life Quality Index (DLQI) questionnaire was used to evaluate the impact of dermatologic disease on quality of life (QoL). [21,22] We found a single previous study reporting on patients' self-recognition of onychomycosis.…”

Small Molecules and Biologics in the Treatment of Nail Psoriasis

“…Nail psoriasis (PsO) is a disorder with profound impact on patients' quality of life (QoL), particularly when considering how limited body surface the nails comprise. Both psychological and functional components of QoL are impaired [1]. It affects up to 50% of patients with cu-taneous PsO, with a lifetime incidence up to 90% [2].…”